Denali Therapeutics Inc.
DNL126
Sanfilippo syndrome type A
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for DNL126 in Sanfilippo syndrome type A are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for DNL126 for Sanfilippo syndrome type A in 2027.”